Last reviewed · How we verify
NCT07269821
Evaluation of a Nutritional Intervention With Dietary Supplements in People Who Have Recently Lost Weight: Effects on Body Composition, Emotional Health, and Gut Microbiota
NA trial testing Metabolaid®-based nutraceutical formulation in GLP-1 in 70 participants. Completed in 30 November 2025.
31 October 2025
Quick facts
| Lead sponsor | University of Alicante |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 July 2025 |
| Primary completion | 31 October 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Metabolaid®-based nutraceutical formulation
- Placebo capsules — full drug profile →
Conditions studied
- GLP-1 — all drugs for GLP-1 →
- Weight Loss Trajectory — all drugs for Weight Loss Trajectory →
- Emotional Disorder — all drugs for Emotional Disorder →
- Microbiota Balance — all drugs for Microbiota Balance →
Sponsor
University of Alicante
Who can join
Adults 25 to 60, any sex, with GLP-1 or Weight Loss Trajectory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the effects of a 12-week nutritional intervention with dietary supplements on individuals who have experienced significant weight loss following the use of GLP-1 receptor agonists or similar weight-loss treatments. The study will investigate whether the combined supplementation protocol can improve body composition, emotional well-being, and gut microbiota diversity after discontinuation of pharmacological treatment. Participants will be randomly assigned to one of two groups: an intervention group receiving a daily combination of food supplements containing bioactive compounds (including polyphenols, prebiotics, and antioxidants) and a placebo group. Both groups will maintain their habitual diet and lifestyle throughout the study. Primary outcomes include changes in fat-free mass, emotional state, and gut microbiota composition. Secondary outcomes include metabolic markers, appetite regulation, and quality of life indicators. This project seeks to provide evidence-based strategies for maintaining health and preventing metabolic rebound following rapid weight loss or pharmacologically induced appetite suppression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07269821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for GLP-1
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07422987 — GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women · recruiting
- NCT07240246 — Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults · NA · active not recruiting
- NCT07270497 — The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of · recruiting
- NCT07042672 — Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity · recruiting
Other University of Alicante trials
Trials by the same sponsor.
- NCT07385794 — Design and Validation of a Personalized Preventive System for Adolescents Based on Biological Maturity, Body Composition · NA · not yet recruiting
- NCT06240364 — Effects of AffronEye®/ Crocuvis+® on Dry Eye Syndrome · NA · not yet recruiting
- NCT07104669 — Sports Nutrition Assessment Program · not yet recruiting
- NCT07531953 — Nutritional Knowledge and Characteristics of HYROX Athletes · recruiting
- NCT07015307 — Sustainable Exercise and Nutrition Programs for Managing Metabolic Disorders in Older Women · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269821 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alicante
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing